UPDATE : Monday, December 9, 2019
상단여백
Will partial success of Biogen’s Alzheimer’s drug lead to FDA approval? by Kim Yun-mi 2019-12-09 14:39
New MSD labor union launched with fresh goals by Jeong Sae-im 2019-12-09 14:37
Gemvax & Kael unveils P2 trial result for Alzheimer treatment by Lee Han-soo 2019-12-06 17:06
AbbVie’s Venclexta nears insurance benefit by Kim Eun-young 2019-12-06 16:35
Syntekabio, CHA Hospital to co-develop immunotherapy by Lee Han-soo 2019-12-06 16:32
라인
Medpacto vows to become global company specializing in biomarker-based drugs by Lee Han-soo 2019-12-06 15:03
Petitioner demands broader benefit for ovarian cancer drug Zejula by Song Soo-youn 2019-12-06 15:02
China OKs Humedix's hyaluronic acid filler by Lee Han-soo 2019-12-06 15:02
‘Lynparza raises value of precision medicine as anticancer treatment’ by Kim Yun-mi 2019-12-05 16:05
Roche Diabetes Care stresses ‘integrated personalized diabetes management’ by Park Gi-taek 2019-12-05 13:01
라인
‘Obesity treatment will drastically change next few years’ by Lee Han-soo 2019-12-04 18:20
'Insulin is safe, natural replacement therapy for diabetic patients' by Lee Han-soo 2019-12-04 17:07
SK Biopharm set to ensure superiority in antiepileptic drug by Jeong Sae-im 2019-12-04 16:18
Hanmi licenses in US firm’s oral immunotherapy candidate by Lee Han-soo 2019-12-04 16:16
ISU Abxis starts trial of Gaucher disease treatment in Australia by Lee Han-soo 2019-12-04 16:16
라인
Samyang Biopharm’s US subsidiary to work on new immunotherapy by Jeong Sae-im 2019-12-03 15:37
Ildong signs co-promotion contract with GSK Consumer Healthcare by Lee Han-soo 2019-12-03 15:18
Global diabetes group opens 5-day show in Busan by Lee Han-soo 2019-12-03 11:04
LG Chem licenses in US firm’s diagnostic platform tech by Lee Han-soo 2019-12-02 13:42
Syntekabio views industry’s crisis as opportunity by Jeong Sae-im 2019-11-29 17:54
여백
여백
여백
Back to Top